Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Co. Ltd.

Division of Samsung Electronics Co. Ltd.
www.samsungbioepis.com

Latest From Samsung Bioepis Co. Ltd.

Samsung BioLogics Vows Improved Management Transparency As Stock Resumes Trade

Following an exchange decision that Samsung BioLogics should remain listed, the company has vowed to improve management transparency by beefing up internal controls and supervision over accounting. The decision is set to ease worries over the possible negative impact of an accounting probe on contract development and manufacturing orders, although the company still faces a court battle with financial authorities over its accounting standards.

South Korea Companies

CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster?

With its final meeting of the year under way, the EMA's medicines evaluation committee, the CHMP, will bring seasonal cheer for some companies if it decides their products merit EU approval. New treatments from Shionogi and Medac are up for an opinion. A planned appearance by Portola before the panel to answers questions relating to its marketing application for Ondexxya/AndexXa has been cancelled and the review period for the marketing authorization application for the product extended.
Europe BioPharmaceutical

Biosimilar Litigation Settlement Score Card: Genentech-Pfizer Herceptin Agreement Is 10th Deal

Genentech inks second settlement of trastuzumab biosimilar litigation; suits ongoing against Amgen, Celltrion/Teva, and Samsung with joint claim construction proceedings.

United States BioPharmaceutical

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Samsung Electronics Co. Ltd.
  • Senior Management
  • Christopher Hansung Ko, PhD, CEO
  • Contact Info
  • Samsung Bioepis Co. Ltd.
    Phone: 32 455 3114
    107, Cheomdan-daero
    Yeonsu-Gu
    Incheon, 406-840
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register